Synlogic’s (SYBX) “Sell (E+)” Rating Reiterated at Weiss Ratings

Synlogic (NASDAQ:SYBX)‘s stock had its “sell (e+)” rating reissued by equities research analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Synlogic Stock Performance

Shares of NASDAQ SYBX opened at $1.74 on Wednesday. The stock has a market cap of $20.30 million, a PE ratio of -21.69 and a beta of 0.55. Synlogic has a fifty-two week low of $0.90 and a fifty-two week high of $1.96. The stock has a fifty day moving average of $1.54 and a 200-day moving average of $1.33.

About Synlogic

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.